Intervacc's distribution partner Dechra launches Strangvac in Finland

Intervacc AB (publ) announces today that its distribution partner, Dechra Pharmaceuticals PLC ("Dechra"), will launch Strangvac in Finland and vaccine vials are expected to be available for delivery shortly. This launch is the result of an extended collaboration between Intervacc and Dechra, where Dechra now has the right to sell Strangvac in Finland. This is a natural development given Dechra's long-standing presence and strong organization in Finland.

“Dechra has a long and successful history in Finland, and it was a natural step for us to give Dechra the opportunity to sell Strangvac in Finland. We look forward to reaching more veterinarians and horse owners with our vaccine Strangvac,” says Jonas Sohlman, CEO of Intervacc.

"We are excited to add this innovative vaccine to our existing broad equine product range and believe this can become a game changer in the approach to strangles" says Marie Jakobsen, Equine Product Manager at Dechra Nordics.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: [email protected]

 

The information was submitted for publication, through the agency of the contact person set out above on May 5, 2025 at 13.15 CET.

About Strangvac

Strangvac, a vaccine against equine strangles, is approved for sale and marketing in the EU, as well as in the United Kingdom, Iceland, Norway, and Liechtenstein. It has been launched in Sweden, Denmark, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland, and Italy.

About Dechra

Dechra Pharmaceuticals is the exclusive distribution partner of Intervacc for the Strangvac vaccine in Europe excluding the Nordic and Baltic countries. Dechra is a global specialist in veterinary pharmaceuticals and related products. Dechra has expertise in the development, manufacturing, marketing and sales of high-quality products exclusively for veterinarians worldwide.

About Intervacc

Intervacc AB (publ) is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins. The Intervacc share is listed on Nasdaq First North Growth Market.

 

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [email protected], Phone: +46 (0)8 – 684 211 10